PE20090967A1 - Derivados de imidazolidina 2,4-diona como moduladores del receptor npy y2 - Google Patents
Derivados de imidazolidina 2,4-diona como moduladores del receptor npy y2Info
- Publication number
- PE20090967A1 PE20090967A1 PE2008001770A PE2008001770A PE20090967A1 PE 20090967 A1 PE20090967 A1 PE 20090967A1 PE 2008001770 A PE2008001770 A PE 2008001770A PE 2008001770 A PE2008001770 A PE 2008001770A PE 20090967 A1 PE20090967 A1 PE 20090967A1
- Authority
- PE
- Peru
- Prior art keywords
- substituted
- phenyl
- npy
- halogen
- cycloalkyl
- Prior art date
Links
- 102000029748 Neuropeptide Y2 receptor Human genes 0.000 title 1
- 150000002461 imidazolidines Chemical class 0.000 title 1
- 108010089579 neuropeptide Y2 receptor Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical group 0.000 abstract 3
- 101710151321 Melanostatin Proteins 0.000 abstract 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 2
- 102100028427 Pro-neuropeptide Y Human genes 0.000 abstract 2
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 abstract 2
- NLEOJRZVVDXEBJ-UHFFFAOYSA-N 5-phenyl-5-propylimidazolidine-2,4-dione Chemical compound C=1C=CC=CC=1C1(CCC)NC(=O)NC1=O NLEOJRZVVDXEBJ-UHFFFAOYSA-N 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 239000004202 carbamide Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/80—Two oxygen atoms, e.g. hydantoin with hetero atoms or acyl radicals directly attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIERE A UN COMPUESTO HETEROCICLICLO DE FORMULA I, DONDE R3 Y R3a JUNTOS SON OXO(=O), O R3 ES H Y R3a ES H O OH; X ES -C(O)-NR6-, -NR6-C(O)- O -NR6-C(O)-NR6-; n ES 0-2; m ES 0-3; R1 ES HALOGENO, CIANO, NITRO, ENTRE OTROS; R2 ARILO SUSTITUIDO O NO, CICLOALQUILO SUSTITUIDO O NO, ENTRE OTROS; R4 ES H, H, HALOGENO, NITRO, HALOGENO, ENTRE OTROS; R5 ES ARILO SUSTITUIDO O NO, CICLOALQUILO SUSTITUIDO O NO, HETEROARILO SUSTITUIDO O NO, ENTRE OTROS; R6 ES H, ALQUILO, CICLOALQUILO. SON COMPUESTOS PREFERIDOS: (+/-)-1-(3,5-DIMETIL-ISOXAZOL-4-IL)-3-{4-[2-(2,5-DIOXO-4-FENIL-4-PROPIL-IMIDAZOLIDIN-1-IL)-ACETIL]-3-FLUORO-FENIL}-UREA, (+/-)-N-{4-[2-(2,5-DIOXO-4-FENIL-4-PROPIL-IMIDAZOLIDIN-1-IL)-ACETIL]-3-FLUORO-FENIL}-3-METIL-BUTIRAMIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES INHIBIDOR DE LOS RECEPTORES NPY Y2 (NEUROPEPTIDO Y) UTILES EN EL TRATAMIENTO DE TRANSTORNOS DE ANSIEDAD Y DEPRESION
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07118602 | 2007-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20090967A1 true PE20090967A1 (es) | 2009-08-10 |
Family
ID=39111624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008001770A PE20090967A1 (es) | 2007-10-16 | 2008-10-15 | Derivados de imidazolidina 2,4-diona como moduladores del receptor npy y2 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20090099243A1 (es) |
| EP (1) | EP2212314A1 (es) |
| JP (1) | JP2011500632A (es) |
| CN (1) | CN101827840A (es) |
| AR (1) | AR068784A1 (es) |
| CL (1) | CL2008003054A1 (es) |
| PE (1) | PE20090967A1 (es) |
| TW (1) | TW200927747A (es) |
| WO (1) | WO2009050200A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7786155B2 (en) * | 2007-10-16 | 2010-08-31 | Novartis Ag | Organic compounds |
| CA2773038A1 (en) | 2009-09-04 | 2011-03-10 | P. Jeffrey Conn | Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN104000816B (zh) * | 2014-05-28 | 2016-03-30 | 中山大学 | 二氧代咪唑烷-酰胺类化合物在制备抗hiv-1病毒药物中的应用 |
| JP7678114B2 (ja) * | 2020-12-31 | 2025-05-15 | 上海医薬集団股▲分▼有限公司 | ＲＯＲγｔモジュレーター、その製造方法および応用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5270317A (en) * | 1990-03-20 | 1993-12-14 | Elf Sanofi | N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present |
| EP0640594A1 (en) * | 1993-08-23 | 1995-03-01 | Fujirebio Inc. | Hydantoin derivative as metalloprotease inhibitor |
| US7317025B2 (en) * | 2003-09-24 | 2008-01-08 | Johnson & Johnson Pharmaceutical Research & Development, Llc | Non-peptidic NPY Y2 receptor inhibitors |
| WO2005090316A1 (en) * | 2004-03-12 | 2005-09-29 | Wyeth | HYDANTOINS HAVING RNase MODULATORY ACTIVITY |
| JP5047168B2 (ja) * | 2005-06-23 | 2012-10-10 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒストン・デアセチラーゼの新インヒビターとしてのイミダゾリノン及びヒダントイン誘導体 |
| TW200730523A (en) * | 2005-07-29 | 2007-08-16 | Wyeth Corp | Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation |
| US7786155B2 (en) * | 2007-10-16 | 2010-08-31 | Novartis Ag | Organic compounds |
-
2008
- 2008-10-15 AR ARP080104489A patent/AR068784A1/es unknown
- 2008-10-15 JP JP2010529371A patent/JP2011500632A/ja active Pending
- 2008-10-15 EP EP08840194A patent/EP2212314A1/en not_active Withdrawn
- 2008-10-15 US US12/251,645 patent/US20090099243A1/en not_active Abandoned
- 2008-10-15 WO PCT/EP2008/063872 patent/WO2009050200A1/en not_active Ceased
- 2008-10-15 CN CN200880112040A patent/CN101827840A/zh active Pending
- 2008-10-15 PE PE2008001770A patent/PE20090967A1/es not_active Application Discontinuation
- 2008-10-15 TW TW097139580A patent/TW200927747A/zh unknown
- 2008-10-16 CL CL2008003054A patent/CL2008003054A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101827840A (zh) | 2010-09-08 |
| EP2212314A1 (en) | 2010-08-04 |
| AR068784A1 (es) | 2009-12-02 |
| CL2008003054A1 (es) | 2009-05-15 |
| WO2009050200A1 (en) | 2009-04-23 |
| TW200927747A (en) | 2009-07-01 |
| JP2011500632A (ja) | 2011-01-06 |
| US20090099243A1 (en) | 2009-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20090816A1 (es) | Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3 | |
| PE20090276A1 (es) | Compuestos derivados de imidazoquinolina como moduladores de tlr7 | |
| PE20141681A1 (es) | Inhibidores de btk | |
| PE20080404A1 (es) | Derivados bencil-amino-piperidina como inhibidores de cetp | |
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| PE20081679A1 (es) | Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de uso | |
| AR083339A1 (es) | Compuestos de quinazolina como bloqueadores de los canales de sodio | |
| PE20081845A1 (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
| PE20080677A1 (es) | Inhibidores de pirrolotriazina cinaza | |
| PE20091201A1 (es) | AMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSINA QUINASA DE BRUTON (Btk) | |
| PE20091095A1 (es) | Moduladores de gamma secretasa | |
| PE20071100A1 (es) | Derivados de azepinoindol como agentes farmaceuticos | |
| PE20141827A1 (es) | Inhibidores de proteinas quinasas | |
| PE20060374A1 (es) | Inhibidores de cinasa heterociclicos fusionados | |
| PE20142400A1 (es) | Compuestos novedosos | |
| PE20071152A1 (es) | Compuestos derivados de azabiciclo[3.1.0]hex como moduladores de receptores de dopamina d3 | |
| NO20073729L (no) | Heterocykliske forbindelser som CCR2B-antagonister | |
| PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
| PE20041078A1 (es) | Derivados heterociclicos inhibidores de la elastasa leucocitica humana (elh) | |
| PE20090601A1 (es) | Derivados de piridin-il-oxi-piridinas como inhibidores de alk5 | |
| AR049696A1 (es) | Derivados de indol | |
| PE20090592A1 (es) | Nuevos derivados de piperazina-amida | |
| PE20081315A1 (es) | Derivados de benzimidazol como antagonistas de vr-1 | |
| PE20090679A1 (es) | Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3 | |
| PE20090621A1 (es) | Pirrolidina-aril-eteres como antagonistas de receptores de nk3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |